A currently marketed recombinant FVIII product is associated with a higher risk of inhibitor development in boys with severe hemophilia A This result, validated by extensive sensitivity analyses, confirms a recently published study and cannot be explained by identified biases
Introduction
Hemophilia A (HA) is a hereditary coagulation disorder due to factor VIII (FVIII) deficiency. 1 Treatment consists of infusions of FVIII concentrates prepared from human plasma or by genetic engineering. 2 Some patients develop neutralizing antibodies against these products, mostly within the first 50 exposure days (EDs). These so-called inhibitors may jeopardize the patient's life 3 and render their therapeutic management more complex 4, 5 and costly. 6 Inhibitors arise in 15% to 35% of children with severe HA. 7, 8 Several genetic and non-genetic risk factors for inhibitor development have been described. The main non-genetic risk factors are related to the modalities and circumstances of replacement therapy, such as age at treatment initiation, the FVIII product used, treatment intensity, prophylaxis regimen, major bleeds, and surgical procedures. [9] [10] [11] Research into inhibitor development has focused on the FVIII source, i.e. recombinant (r) versus plasma-derived (pd) products, with mixed results. 12, 13 In 2004 a cohort study was 14 The only significant result was an unexpectedly higher risk of inhibitor development with a second-generation full-length rFVIII product (Product "D") compared with the most widely used third-generation rFVIII product. This result perplexed prescribers and hemophilia patients worldwide. 15, 16 Quickly, the European Medicines Agency (EMA) launched a review of the RODIN results. 17 In December 2013, EMA concluded that the available data did not support a higher inhibitor incidence with Product D than with other products. However, no new data challenged the RODIN findings, and it thus remained to be shown whether the observed difference was real or simply due to bias or chance (sampling fluctuations). In France, a prospective cohort was created in 1994 by the public health authorities to monitor hemophilia treatment safety. 18 A sub-cohort of previously untreated patients (PUPs) was established to investigate risk factors for inhibitor development. Here we compared inhibitor incidence rates across rFVIII products in these PUPs with severe HA.
Patients and methods

Patients
Almost all hemophilia patients in France have been included in the FranceCoag national pharmacosurveillance network, based on voluntary participation of all French HTC centers without support from pharmaceutical companies.
Children included in the PUP cohort are closely monitored until age 18 years. Children born before 2000 were eligible if they have fewer than 4 EDs to FVIII, while those born from 2000 onwards are included at diagnosis or as early as possible, provided their first infusions are traceable. The research into the differences between inhibitor development incidences in rFVIII and pdFVIII products is still relevant. However the RODIN findings prioritized a comparison of rFVIII product immunogenicities to check whether or not this class is homogeneous. We therefore selected boys with
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From FVIII activity below 0.01 IU/mL enrolled in the FranceCoag PUP cohort and first treated with rFVIII products. To facilitate the interpretation of both studies' results, patients who also participated in the RODIN study were excluded from our analyses. The protocol of this observational cohort was approved by the French data protection watchdog.
The parents or legal guardians received detailed written information about the objectives and modalities of the followup and were asked to approve their child's enrollment in accordance with the Declaration of Helsinki.
Data collection
Data were collected on electronic case report forms. Baseline data comprised demographic characteristics, HA-related medical history from birth, the F8 gene defect, family history of hemophilia and inhibitors, and ethnic origin. At each follow-up visit, major events having occurred since the last visit were collected (severe bleeds, hemarthrosis, surgical procedures, vaccinations), together with detailed hemophilia treatments. The results of FVIII and inhibitor assays performed during follow-up were also recorded. The collected data were automatically checked and repeatedly monitored for completeness and inconsistencies by three dedicated clinical research assistants (CRA) in the HTCs.
Independently from FranceCoag Network, the French Hemophilia Association publishes a customized booklet for collecting the adhesive labels of all injected FVIII or IX products in order to obtain details of home treatment. For several decades, this tool has been distributed to hemophilia patients in all French HTCs. In addition to data collected during hospitalization, this booklet allowed us to record the first 75 EDs in the same way as in the RODIN study, including the infusion dates, FVIII product brands and doses, indications, bleeding events, and types of surgery. These additional data were collected by a fourth CRA, independently of the basic data collection. Thus, any discrepancy between the two recording systems (regarding the date of the first infusion, FVIII products received, number of EDs at the date of inhibitor detection, initiation of regular prophylaxis, surgical procedures, and severe bleeding episodes) triggered extensive investigations based on the original files.
Follow-up and outcomes
Patients enrolled in the FranceCoag Network are followed indefinitely, but only the first 75 EDs were considered for this analysis. The cut-off date was May 19, 2014. For patients who developed an inhibitor, follow-up ended on the last ED before its detection. The follow-up was censored after the last rFVIII infusion in case of switch to a pdFVIII before ED75 or if the patient had not reached 75 EDs at the last clinical visit. The inhibitor assays were performed in the laboratory of each HTC. The primary outcome measure was inhibitor development during the first 75 EDs, as defined as a positive assay result (>0.6 Bethesda units (BU)/mL) on any two dates. A secondary outcome measure was inhibitor development during the first 75 EDs with a peak titer of at least 5 BU/mL at any time. 19 A third outcome measure was added to reflect the therapeutical impact of inhibitors, namely inhibitor development during the first 75
EDs, treated at any time with a bypassing agent and/or an immune tolerance induction (ITI). All clinically significant cases were validated by an ad hoc clinical committee using a standardized procedure (supplemental Methods).
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Studied rFVIII products
The main investigated risk factor was the rFVIII product received during the first 75 EDs. Six rFVIII products (A to F) have been marketed worldwide (Table 1) . Products A-C were withdrawn from the European Union market and were replaced with new-generation rFVIII products (D to F) (supplemental Figure 1) . As patients could be switched from one product to another during the first 75 EDs, the rFVIII product was analyzed as a time-varying factor. As in the RODIN article, Product E served as reference.
Primary analysis
We constructed a Cox proportional hazards model with ED as the observational time unit. The best-acknowledged fixed risk factors namely the F8 gene defect, family history of hemophilia and inhibitors, ethnic origin, and age at first rFVIII infusion, were systematically included in the multivariate models, regardless of their statistical association with inhibitor development in this analysis. The following time-varying risk factors were also considered: calendar period, regular prophylaxis, treatment intensity markers as used in the RODIN study (interval between EDs and rFVIII dose calculated over the last five EDs, and peak treatment episodes), history of surgery, 14 and history of severe bleeding.
Time-varying risk factors associated with the "all inhibitors" outcome with a p value <0.2 were retained in the final multivariate models. Crude and adjusted HRs are reported for the association between a given rFVIII product and clinically significant inhibitor development. Associations were considered significant if p <0.05. Cofactor definitions, grouping and missing-data procedures are described in the supplemental Methods.
Sensitivity analyses
We performed ten sensitivity analyses. In the first nine analyses, the study population was rendered more homogeneous by excluding 1) patients included in a rFVIII product clinical trial; or by selecting 2) patients with an 
Meta-analysis
We combined adjusted D/E HRs of the RODIN study and our study using indirect log hazard ratio and variance estimation 21 for "all inhibitors" and high-titer inhibitors outcomes. The degree of inconsistency across both studies was estimated by the I 2 statistic.
22
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From (Table 2) , only the calendar period at the first infusion was significantly associated with the first rFVIII product received (p<0.001), owing to the products' staggered market release dates. Among the boys' time-varying risk factors, a regular prophylaxis regimen was initiated within the first 50 EDs in 47.9% of patients. At least one peak treatment episode lasting at least 3, 5, and 10 consecutive days, respectively, was experienced by 69.3%, 39.9%, and 13.5% of patients. Similarly, at least one surgical procedure and at least one severe bleeding episode were experienced by respectively 12.5% and 11.6% of patients. Only the initiation of regular prophylaxis within first 50 EDs was significantly associated with the first rFVIII product received (p=0.047 for global test).
Follow-up and exposure
The observation period totaled 478 person-years and 14 044 EDs. Follow-up data are shown in the supplemental Table 2 according to the first product received. In total, 274 boys (90.4%) received a single rFVIII product throughout follow-up. The other 29 boys switched at least once to another rFVIII product (supplemental Table 3 ). Most switches were from a first-generation rFVIII product to a second-or third-generation rFVIII product of the same brand. Five of these boys developed an inhibitor. The contributions in EDs according to the rFVIII product received during the follow-up and the seven studied time-varying risk factors are shown in supplemental Table 4 .
Inhibitor characteristics
1417 inhibitor assay results were recorded. On average, these assays were performed every 6.3 EDs during the first 25
EDs and every 9.9 EDs during the overall follow-up period. The assay frequency was very similar across the rFVIII products (supplemental Table 5 ). A clinically significant inhibitor was diagnosed in 114 boys (37.6%) after a median of 13 EDs (interquartile range -IQR: [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and at a median age of 15.2 months (IQR: 11.1-22.8) (Table 3) . Among these boys with inhibitors, 95 (83.3%) were subsequently treated with a bypassing agent and/or ITI at any time during
FranceCoag follow-up. The cumulative incidence at ED75 was 40.2% (95%CI: 34.8-46.2). A high-titer inhibitor was diagnosed in 63 boys (20.8%), with a cumulative incidence of 23.9% (95%CI: 19.1-29.6) at ED75 (supplemental Figure 3) . A clinically significant inhibitor was diagnosed only in 3 boys between ED50 and ED75 and no cases were diagnosed between ED75 and ED100 among the 303 selected boys.
Primary analysis
The risk of inhibitor development was different across the four studied rFVIII products for the "all inhibitors" outcome (p=0.025) and also for the "treated inhibitors" outcome (p=0.019) ( Table 4 
Sensitivity analyses
Detailed results of the ten sensitivity analyses are shown in supplemental Tables 6 to 15 . Estimated aHRs were between 1.52 and 2.59 for the "all inhibitors" outcome across the primary analysis and the ten sensitivity analyses; between 1.29 and 2.00 for the high-titer inhibitors outcome; and between 1.47 and 2.39 for the treated inhibitors outcome ( Figure 2 ). Wide HR CIs were observed for Products A and C, particularly in sensitivity analyses with reduced populations, and no stable trend was detected. Finally, the higher risk associated with Product D versus Product E was stable, at approximately 60%, for the three outcomes. p-values were lower to 0.2 for "all inhibitors" and treated inhibitors outcomes.
Meta-analysis
The RODIN-FranceCoag combined D/E aHR was 1.58 (95% CI 1.17 to 2.14) for all inhibitors and 1.70 (1.15 to 2.52) for high-titer inhibitors (Figure 3) . No heterogeneity was observed between the RODIN and the FranceCoag studies for both outcomes (I 2 =0%).
Discussion
Main findings
A publicly funded pharmacosurveillance system for antihemophilia drugs has existed in France since 1994. We took advantage of this dataset to challenge the unexpected and disturbing finding of the RODIN study.
14 RODIN and
FranceCoag are both cohort studies recording precisely the first EDs of replacement therapy in real-life conditions.
The cumulative incidence rates of inhibitor development by ED75 were 32.4% and 40.2% for all inhibitors, and 22.4% and 23.9% for high-titer inhibitors in RODIN study and our study respectively.
We observed a significant association between the rFVIII product received and the "all inhibitors" outcome. More specifically, after taking known major genetic and non-genetic cofactors into account, the D/E aHR was 1.55 (95% CI 0.97 to 2.49). The D/E aHR was 1.56 (0.82 to 2.98) for high-titer inhibitors and 1.58 (0.94 to 2.64) for treated inhibitors. The events number in our study is lower than in the RODIN study and leads to a lower analysis power.
However the difference between inhibitor incidence with Products D and E persisted in ten sensitivity analyses based on more homogeneous subgroups and different statistical approaches. Meta-analysis of the RODIN and FranceCoag results showed a concordant and significant 60% higher risk with Product D compared with Product E for the "all inhibitors" and high-titer inhibitor outcomes. In contrast, in the literature only nine (15%) of 60 PUPs and minimally treated patients (MTPs) enrolled in registration trials of Product D developed inhibitors, 23, 24 and postmarketing studies showed even lower rates (supplemental Table 21 ). 25, 26 One key difference with cohort studies is that patients are not selected, whereas clinical trials exclude some patients at an increased risk of inhibitor development, such as those requiring intensive initial treatment because of early severe bleeding.
Strengths and potential biases
The prevalence of HA at birth in France from 1991 to 2008 was estimated at 23.3 cases per 10 5 male live births (supplemental Table 1 ). This result, that represents one of the highest rates observed in an industrialized country, 27 supports the exhaustiveness of the FranceCoag Network. All but five of the boys with severe HA born since 2000 met the enrollment criteria for the PUP cohort. Among the 370 PUPs with severe HA treated with rFVIII, only 17 (4.6%)
were excluded due to insufficient data. 28 It is therefore unlikely that such a prescription bias occurred in either cohort. Furthermore, the three main genetic risk factors were included in both multivariate analyses. High-titer inhibitors are usually diagnosed after hemorrhagic events or ineffective replacement treatment, and any underreporting would preferentially concern low-titer inhibitors. Such a bias might be envisaged if the frequency and/or sensitivity of inhibitor screening assays varied according to the rFVIII product received. As the calendar period clearly influenced the choice of product and might have affected the outcome assessment, 7,15 we considered it in multivariate analyses. Furthermore, Products D and E were used during concurrent time periods (supplemental Figure   1 ). Differences in practices across HTCs with respect to both the choice of rFVIII products and outcome assessments are also conceivable, but such variations would have been limited because our study took place in a single country.
Furthermore, no difference in inhibitor assay frequency was observed between Product D and Product E (supplemental Table 5 ). We obtained similar results when we restricted the analysis to patients treated in the 13 most contributory HTCs, and when we included the HTC effect in multivariate analysis (supplemental Table 13 ).
Ultimately, similar results were observed after successively removing the data for each of the 13 most contributory
HTCs and in the 20 less contributory HTCs (supplemental Table 20 ). We addressed potential genetic confounding factors by taking most of them into account in multivariate analysis. While greater precision would be desirable,
16,29
we could only compare two classes of F8 gene defects, due to limited subgroup sizes. Again, similar results were obtained in patients belonging to the largest homogeneous class (intron-22 inversion) (supplemental Table 7 ). Other highlighted genetic inhibitor risk factors were HLA genotype [30] [31] [32] and polymorphisms in immune regulatory genes. 33, 34 In clinical practice these genetic markers are rarely investigated and there is no argument to support their possible influence in the FVIII product choice. Genetic risk factors are thus unlikely to have played a confounding role. The best-known potential non-genetic confounding factors, namely replacement treatment intensity 35 and related conditions (surgical procedures and severe bleeds), were factored into our multivariate analyses, in addition to regular prophylaxis.
Possible biological explanations and implications
A main difference between Product D and Product E is that the former is produced in baby hamster kidney (BHK) cells and the latter in Chinese hamster ovary (CHO) cells. Changes in BHK manufacturing practices between Product
B and Product D might have led to increased immunogenicity, 36 but the number of patients treated with Product B in both the RODIN study and our cohort was too small for comparison with Product D. rFVIII produced by BHK and CHO cells differ in several respects, such as the degree of tyrosine residue sulphation and type of glycosylation. 37 The presence of specific glycan chains might affect dendritic cell uptake and thereby modify rFVIII immunogenicity.
38
The amino-acid sequence of the BHK rFVIII products (B and D) corresponds to the most frequent haplotype (H1) in the Caucasian population. 39 Full-length CHO rFVIII products (A and E) have an amino-acid difference at B-domain position 1241, but no substantial interaction was found between the patient's F8 haplotype, rFVIII product received, and inhibitor risk. 40 Furthermore these products also differ in their biological activities. 41 In fact, the mechanism of the difference in inhibitor incidence between rFVIII remains unclear and not elucidated by the present study. Non-clinical
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From studies will thus be necessary to identify the mechanism underlying the difference in immunogenicity between Products D and E. However it is conceivable that a slight difference in immunogenicity among rFVIII products could lead to a moderate increase in the risk of inhibitor development. 42 Unfortunately, few if any other HA PUP cohorts exist worldwide, ruling out further epidemiological results. The consistency between our findings and those of the RODIN study suggests (but not proves) that the observed association between rFVIII products and the risk of inhibitor development is causal. The potential impact of the higher risk of inhibitor development associated with Product D could be estimated to one or two annually extra cases in France (supplemental Results). Thus, we think that these results concerning a major adverse effect are sufficiently convincing to warrant consideration in the choice of rFVIII products for PUPs with severe HA in France and in other countries.
American and European medicines agencies recognize that registration trials with small numbers of selected patients may not be able to detect a moderate difference in FVIII immunogenicity. Several initiatives were implemented in the past decade to improve our knowledge of the association between FVIII products and inhibitor incidence. The ongoing Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) trial was launched in 2009 to compare incidence of inhibitors with vWF-containing pdFVIII products versus rFVIII products in PUPs with severe HA. 43 The expected number of patients in the rFVIII arm may be too small to demonstrate a difference within this group. To our knowledge, no other randomized trials comparing FVIII products are planned, owing particularly to the rarity of HA and the very young age of the target population. In the United States, the Centers for Disease Control and Prevention began the Hemophilia Inhibitor Research Study in 2006 to determine the feasibility of using a public health surveillance system to collect key information about inhibitors. 44 This feasibility study has not yet been able to produce results for PUPs with HA, but national implementation of this inhibitor surveillance is being considered. The
European Hemophilia Safety Surveillance System (EUHASS) was established concurrently. 45 Adverse events and data for exposed populations are periodically reported, but a stable number of patients treated with a particular product over at least a two-year period is required to estimate the cumulative incidence of inhibitors (at ED50 in PUPs) with this product. 46 This could limit the precision of product comparisons in this pharmacovigilance program. Our findings and those of the RODIN study highlight the need to strengthen the power and responsiveness of post-marketing monitoring of hemophilia treatments worldwide. This is a major issue as several new FVIII products, including human-cell derived and long-acting rFVIII, are reaching an advanced stage of their clinical development and should be marketed shortly in numerous countries. Given the heavy burden of inhibitors for individual patients and the high costs of bypassing agents and ITI, this mobilization would not only benefit patients but would also lead to substantial savings for national healthcare budgets. C.R. has received support for attending scientific meetings and honoraria (speaker fees/consultant in advisory boards) from Baxter Bioscience, CSL Behring, LFB, Novonordisk, Pfizer and SOBI; has been an investigator in studies sponsored by Baxter, CSL Behring, LFB and Pfizer; and has received research support from CSL Behring and Novonordisk (none of these relate to the present study).
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